For pancreatic ductal adenocarcinoma (PDAC), targeting USP22 has been shown to enhance the response to immunotherapy and associated with increased proportions of CD8 + T cells and NK cells, which turn “cold” tumor into “hot” (Fig. 2B) [100]. This evidence concerns the gene CD8A and neoplasm.